MedTrace Logo

Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease

NCT00005024 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2014-01-06

No results posted yet for this study

Summary

RATIONALE: Antiemetic drugs such as granisetron may help to prevent nausea and vomiting in patients treated with chemotherapy.

PURPOSE: Randomized phase III trial to compare the effectiveness of granisetron with that of a placebo in preventing nausea and vomiting after chemotherapy in patients who have malignant disease.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

carboplatin

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

granisetron hydrochloride

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Barbara J. Gitlitz, MD · Jonsson Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005024 on ClinicalTrials.gov